# LIfT BioSciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lift-biosciences

- Industry: Biotechnology
- Headquarters: London, UK
- Website: www.liftbiosciences.com/
- Total disclosed funding: $13M
- Latest round: Series A (May 7, 2024)
- Investors on record: 3

## About

Based in London, UK, and founded in 2016, LIfT BioSciences Ltd operates as a provider of biotechnology solutions using alpha neutrophil cell therapy. LIfT BioSciences develops breakthrough cell therapies to treat solid tumors using its own product, Immuno-Modulatory Alpha Neutrophils (IMANs). These treatments work by directly targeting and eliminating cancer cells while also stimulating the immune system to recognize the tumor. The company operates in the United Kingdom and throughout Europe, serving healthcare practitioners and patients. The firm's mission is to meet substantial medical requirements in the treatment of solid tumors. LIfT BioSciences Ltd earns revenue by developing and licensing patented neutrophil-based immuno-oncology cell therapies, partnering for clinical trials, and securing grants plus strategic collaborations. In July 2025, LIfT BioSciences Ltd received EUR 11.9 million in grant funding from Enterprise Ireland. The company plans to use the funding from July 2025 to advance its N-LIfT platform, support manufacturing processes, and conduct a human trial of IMAN therapy for solid tumors.

## Funding rounds

- Series A, May 7, 2024, $13M — Starbloom Capital, LifeSpan Vision Ventures, Sijbrandij Foundation

## Investors

- Starbloom Capital (https://capitalatlas.ai/funds/starbloom-capital) — Series A
- LifeSpan Vision Ventures (https://capitalatlas.ai/funds/lifespan-vision-ventures) — Series A
- Sijbrandij Foundation — Series A